摘要 : Abstract Adjuvant chemotherapy has become standard of care for pancreatic ductal adenocarcinoma (PDAC) as it improves patient outcome. However, its clinical meaning in early‐stage, UICC I tumors remains uncertain. We examined the... 展开 Abstract Adjuvant chemotherapy has become standard of care for pancreatic ductal adenocarcinoma (PDAC) as it improves patient outcome. However, its clinical meaning in early‐stage, UICC I tumors remains uncertain. We examined the effect of adjuvant therapy on disease‐free survival (DFS) and overall survival (OS) of UICC stage I PDAC patients treated at an academic tertiary care center between 2000 and 2016. Among 124 patients (69 male, 55 female; median age 68?years, range 41‐84?years) with UICC stage I disease, adjuvant therapy improved both DFS (19.8 vs 12.8?months, HR 0.59, 95% CI: 0.37‐0.94, P?=?.03) and OS (40.9 vs 20.3?months, HR 0.54, 95% CI: 0.35‐0.84, P?=?.005). Multivariate analyses and propensity score matching confirmed the prognostic impact of adjuvant therapy independent of localization, differentiation and R‐status. Thus, every patient with UICC I PDAC should receive adjuvant chemotherapy as it may improve outcome significantly. Our findings support the concept of PDAC as systemic disease from early stages on. 收起